Cargando…
REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548756/ http://dx.doi.org/10.1016/j.chest.2022.08.707 |
| _version_ | 1784805503928369152 |
|---|---|
| author | WILLIAMS, STEPHANIE N WALO JR, RICHARD LATTANZIO, NATALIA DAWKINS, KEVIN K ABDELAL, QASSEM HAMAD, KAREN WIESE-ROMETSCH, WILHELMINE |
| author_facet | WILLIAMS, STEPHANIE N WALO JR, RICHARD LATTANZIO, NATALIA DAWKINS, KEVIN K ABDELAL, QASSEM HAMAD, KAREN WIESE-ROMETSCH, WILHELMINE |
| author_sort | WILLIAMS, STEPHANIE N |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9548756 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American College of Chest Physicians. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95487562022-10-11 REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS WILLIAMS, STEPHANIE N WALO JR, RICHARD LATTANZIO, NATALIA DAWKINS, KEVIN K ABDELAL, QASSEM HAMAD, KAREN WIESE-ROMETSCH, WILHELMINE Chest Critical Care American College of Chest Physicians. Published by Elsevier Inc. 2022-10 2022-10-10 /pmc/articles/PMC9548756/ http://dx.doi.org/10.1016/j.chest.2022.08.707 Text en Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Critical Care WILLIAMS, STEPHANIE N WALO JR, RICHARD LATTANZIO, NATALIA DAWKINS, KEVIN K ABDELAL, QASSEM HAMAD, KAREN WIESE-ROMETSCH, WILHELMINE REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS |
| title | REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS |
| title_full | REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS |
| title_fullStr | REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS |
| title_full_unstemmed | REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS |
| title_short | REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS |
| title_sort | remdesivir plus dexamethasone vs tocilizumab or baricitinib supplementation initiated inside 48 hours of index covid-19 hospitalization in icu patients |
| topic | Critical Care |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548756/ http://dx.doi.org/10.1016/j.chest.2022.08.707 |
| work_keys_str_mv | AT williamsstephanien remdesivirplusdexamethasonevstocilizumaborbaricitinibsupplementationinitiatedinside48hoursofindexcovid19hospitalizationinicupatients AT walojrrichard remdesivirplusdexamethasonevstocilizumaborbaricitinibsupplementationinitiatedinside48hoursofindexcovid19hospitalizationinicupatients AT lattanzionatalia remdesivirplusdexamethasonevstocilizumaborbaricitinibsupplementationinitiatedinside48hoursofindexcovid19hospitalizationinicupatients AT dawkinskevin remdesivirplusdexamethasonevstocilizumaborbaricitinibsupplementationinitiatedinside48hoursofindexcovid19hospitalizationinicupatients AT kabdelalqassem remdesivirplusdexamethasonevstocilizumaborbaricitinibsupplementationinitiatedinside48hoursofindexcovid19hospitalizationinicupatients AT hamadkaren remdesivirplusdexamethasonevstocilizumaborbaricitinibsupplementationinitiatedinside48hoursofindexcovid19hospitalizationinicupatients AT wieserometschwilhelmine remdesivirplusdexamethasonevstocilizumaborbaricitinibsupplementationinitiatedinside48hoursofindexcovid19hospitalizationinicupatients |